NTRC Therapeutics is a precision medicine company that is specialized in discovery and development of innovative kinase inhibitors to treat cancer patients. Using its proprietary EPriL platform NTRC Therapeutics is now developing next-generation kinase inhibitors to treat acquired drug resistance observed in cancer patients treated with first generation inhibitors.